Prostate Cancer

Men from racially and ethnically underserved communities are more likely to be diagnosed with advanced prostate cancer.

Men in these communities are less likely to receive routine PSA screenings, a blood test that can help detect prostate cancer early. As a result, prostate cancer is often diagnosed at later stages, when treatment options may be more limited.

African American and Hispanic/Latino men, in particular, face barriers to timely prostate cancer care, including reduced access to screening, specialty care, and treatment. They also experience longer delays between diagnosis and treatment, which contributes to poorer outcomes and lower survival rates.

When we share our health care journeys, we help raise awareness and encourage others in our communities to seek screening and care earlier—actions that can lead to better outcomes and save lives.

Patient stories

Hear real patients stories from patients like you.

“…after my prostate cancer surgery, I learned two men in my family had been diagnosed.

Family history is critical for doctors and impacts their decisions — including when to start screenings, especially because in Black men prostate cancer may start earlier and have no symptoms until it is advanced.”

—Mical, Prostate Cancer Survivor

Interested in sharing your story? If you participate, you will be paid for your time.

African American Community

African American men are more than 1.5 times more likely to develop prostate cancer than White men.

Compared to non-Hispanic White men, African American men are nearly 2.5 times more likely to die from prostate cancer.

Outcomes are worse for African American men because they are less likely to be screened or to receive treatment for prostate cancer.

What is the PSA test?

Prostate-specific antigen, or PSA, is a protein produced by the prostate. The PSA test is a blood test that measures the level of PSA in the blood. The level of PSA is often higher in people with prostate cancer.

The PSA test was initially approved by the FDA in 1986 to monitor a man’s prostate cancer after they were diagnosed.

Laurean, Certified Physician Assistant

The importance of regular PSA screenings

In 1994, the FDA approved the PSA test to be used to aid in diagnosing prostate cancer in men 50 years of age and older. It is recommended to begin PSA screening earlier than 50 in specific populations that are at higher risk for prostate cancer.

The American Urology Association recommends PSA testing starting at age 40 for African American men due to their higher risk of getting prostate cancer.

Please speak to your doctor about getting a PSA screening, even if you do not have any symptoms.

Men can have prostate cancer without experiencing any symptoms. Getting regular screenings can help identify and diagnose prostate cancer earlier, which can increase your chances of successful treatment.

What if you have been diagnosed with prostate cancer?

First, don’t lose hope. There are many FDA-approved treatment options, even to treat more advanced prostate cancer. Work with your doctor and consult with an oncologist, a specialist who identifies and treats cancers.

Have you considered joining a clinical trial?
If you are interested in joining a clinical trial or if you want to learn more—Let’s get connected. We can help you identify a clinical trial that is the best fit for you.

Interested in sharing your story?
We want to hear from you. We must raise our voices to ensure that health care works for all of us. If you are selected, you will be paid for your time.

Connect with a patient advocate

Anita

The information on this site is for educational purposes only and does not constitute medical advice. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with questions about your medical condition. In a medical emergency, call your doctor or emergency services immediately. CHMConnect does not endorse any specific tests, physicians, products, procedures, or opinions on this site. Use of this information is at your own risk. - © 2026 CHMConnect™. All rights reserved.